Myasthenic Crisis Management

Clinical Presentation and Diagnosis

Dysarthria (slurred speech) is a bulbar manifestation of myasthenic crisis, indicating severe bulbar muscle weakness, according to Praxis Medical Insights 1
Facial muscle weakness is a symptom of myasthenic crisis, contributing to the diagnosis of this condition, as noted by Praxis Medical Insights 1, 2
Severe proximal muscle weakness affecting limbs and trunk is a characteristic of myasthenic crisis, as described by Praxis Medical Insights 1, 2
Neck weakness preventing head support is a symptom of myasthenic crisis, as indicated by Praxis Medical Insights 2
Fatigability, with symptoms worsening with continued activity, is a key clinical characteristic of myasthenic crisis, according to Praxis Medical Insights 2
Bilateral but potentially asymmetric presentation is a feature of myasthenic crisis, as noted by Praxis Medical Insights 2

Pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC) is essential to quantify respiratory compromise in myasthenic crisis, as recommended by the Journal of Clinical Oncology 3, 4, 1
Acetylcholine receptor (AChR) antibodies in blood are a confirmatory test for myasthenic crisis, with nearly all generalized MG patients testing positive, according to the Journal of Clinical Oncology and Praxis Medical Insights 3, 1, 2
Single-fiber EMG with jitter studies has a sensitivity of >90% in generalized MG, making it a valuable diagnostic tool, as noted by Praxis Medical Insights 1

Medications that can precipitate or worsen myasthenic crisis, such as β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics, must be avoided, as warned by the Journal of Clinical Oncology and Praxis Medical Insights 3, 4, 5, 2, 1
Pyridostigmine is a recommended anticholinesterase therapy for myasthenic crisis, starting at 30 mg orally three times daily, as suggested by the Journal of Clinical Oncology and Praxis Medical Insights 3, 4, 1
Approximately 50% of patients may show minimal response to anticholinesterase therapy alone, highlighting the need for combination therapy, according to Praxis Medical Insights 1, 5

Daily neurologic evaluation and frequent pulmonary function assessment are crucial for monitoring patients with myasthenic crisis, as recommended by the Journal of Clinical Oncology 3, 4
Autonomic dysfunction and complications such as infections, delirium, and aspiration pneumonia must be monitored and addressed promptly, as noted by the Journal of Clinical Oncology 3
Immune checkpoint inhibitors should be permanently discontinued in patients with Grade 3-4 myasthenia gravis, as advised by the Journal of Clinical Oncology 3, 4